Electronic Cigarettes, Nicotine and Policy Implications

Similar documents
RE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health

ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?

Exploring five common claims about e-cigarette use. Lion Shahab, PhD University College

Cardiovascular effects of nicotine vs. cigarette smoke

Public consultation on SCENIHR preliminary report on "Health Effects of Smokeless Tobacco Products"

Dual Use: If Electronic Cigarettes are so good, why are there so few exclusive users?. Jonathan Foulds, PhD

Nicotine Reduction: Harm Reduction not Prohibition

Introduction. Principles

RISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS

Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment

Low-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation

Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA. No disclosures

Responsible Practice in E-Vapour Products (EVP) Product Stewardship

TREATMENT OF TOBACCO USE DISORDERS E-CIGS & APPS

Stop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN

FORMs of TOBACCO. 2 nd of 3 Prep for Session 1

A combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.

Prevent disease Protect from injury Promote healthy lifestyles

OVERALL HEALTH EFFECTS OF SWEDISH MATCH SNUS PRODUCTS

TMA Annual Conference, Williamsburg, May 20-22, Public Health. The Swedish Experience

National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes

Tobacco Cessation, E- Cigarettes and Hookahs

E-Cigarettes: Current Perspective

Compensatory smoking from gradual and immediate reduction in cigarette nicotine content

16851 Mount Wolfe Road Caledon ON L7E 3P or 1 (855)

Product Standards for Reducing Nicotine in Cigarettes

AHEC Tobacco Online Modules

The Burden of Tobacco, Tobacco Control, and Advocacy: Policy Strategies for Oral Health. Robert McMillen, PhD

NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

Epidemiological evidence on snus (Swedish moist snuff) and health in adults. By Peter Lee

Is Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Community Care Behavioral Health Organization

Heat-not-Burn Products: Scientific Assessment of Risk Reduction

HHS Public Access Author manuscript J Patient Cent Res Rev. Author manuscript; available in PMC 2016 February 04.

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

Public Health England s Independent Expert E-Cigarettes Evidence Review

SAFETY E-CIGS: CLINICAL STUDIES

Jackson Tobacco Reduction Coalition 1715 Lansing Avenue, Jackson, MI Phone (517) FAX (517)

Tobacco Cessation for Women of Reproductive Age. Erin McClain, MA, MPH

Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re

00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Disclosures. Terms and Definitions 3/30/2017. Cardiovascular Consequences of Secondhand Tobacco Smoke Exposure in Youth

The concept that not all tobacco and nicotine products

How to Regulate E-Cigarettes? Are we asking the right questions?

The gateway theory. Pr Jean-François ETTER PhD (political science) E-cigarette Summit London, November 17, Competing interests: none

MDQuit Best Practices Conference January 26, Presented by William C. Tilburg Deputy Director

Communicating the Risk of Nicotine Delivery Products

COMMENT PREPARED AFTER THE TPSAC MEETIING ON CAMEL SNUS. significantly reduce harm to individuals or benefit population health.

The Latest on Vaping Among U.S. Teens

TOBACCO PLAYBOOK DÉJÀ VU: E-CIGARETTES

Non-Industry Voices on Tobacco Harm Reduction and Vaping Products

Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?

E-Cigarettes and Vapes

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

Population impacts of snus tobacco initiation and cessation

Cigarettes and Other Nicotine Products

Understanding the Impact of Cigarette Smoking Using Brain Imaging

E-cigarettes and personal vapourisers: current research and policy

Cigarettes and Other Tobacco Products

BASIC SKILLS FOR WORKING WITH SMOKERS

Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21

TOBACCO PRODUCT OR MEDICAL PRODUCT?

Electronic Nicotine Delivery Systems

Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences

Smoking and CVD. .what role for the Cardiologist? Dr Sandeep Gupta, MD, FRCP

An Evolving Perspective on Smoking Cessation Therapies

RADM Patrick O Carroll, MD, MPH Senior Advisor, Assistant Secretary for Health, US DHSS

The importance of offering adult smokers a portfolio of potentially less harmful products

The Voice of Local Public Health in New York State. May 12, 2014

Nicotine pharmacokinetics of electronic cigarettes: experimental data and a review of the literature

Tobacco endgames in Australia

E-cigarettes vs. Conventional Cigarettes and their Health Effects on the Environment. Elizabeth Do 5/01/15 GCH 360

Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data

Electronic Cigarettes: What They Are, How They re Marketed, & How We Can Protect Our Youth

CHEMISTRY of NICOTINE PHARMACOLOGY NICOTINE ABSORPTION: BUCCAL (ORAL) MUCOSA NICOTINE ABSORPTION. NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION

Sweet Cheap Easy to Get. Tobacco industry tactics. Introduction. Tobacco Industry Tactics 5/1/2018

Tobacco Data, Prevention Spending, and the Toll of Tobacco Use in North Carolina

Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes

Tobacco Prevention ACMS SIXTH GRADE UNIT

FDA s Nicotine Steering Committee should develop policies, regulations, and procedures that promote cessation and increase the use of proven therapies

Use of e-cigarettes (vapourisers) among adults in Great Britain

Executive Summary. No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018

REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD

REVIEWS 1. Cardiovascular effects of electronic cigarettes

Electronic cigarettes for smoking cessation

Nicotine: Everything You Need to Know but Have Never Been Told

Smoking cessation and weight gain

SACTob Position Statement on Nicotine and Its Regulation in Tobacco and Non-Tobacco Products.

BASIC SKILLS FOR WORKING WITH SMOKERS

Population-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge

Alcohol and Tobacco Jeopardy. 10th Grade Health

Electronic Cigarette Use and Respiratory Symptoms in Chinese Adolescents in Hong Kong. Title. Wang, MP; Ho, DSY; Leung, LT; Lam, TH

A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.

Electronic cigarettes disruptive innovation, public health potential and regulatory challenge

UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY

E-cigarettes surpass tobacco cigarettes among teens

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

The Evidence on E-cigarettes: Evaluating What We Have and Identifying What We Need

Transcription:

Electronic Cigarettes, Nicotine and Policy Implications Neal L Benowitz MD University of California San Francisco The E-Cigarette Summit The Royal Society London November 17, 2016

Disclosures Dr Benowitz has been a consultant to pharmaceutical companies that market smoking cessation products, including Pfizer and GlaxoSmithKline and a paid expert in litigation against tobacco companies

My Big Picture Questions What are the harms of long-term use of nicotine delivered without tobacco combustion (e-cigarettes or other ANDS)? How best to regulate nicotine to eliminate cigarette smoking?

Outline Major nicotine safety concerns ECs and nicotine addiction in youth Daily nicotine exposure with various patterns of EC use Harms of nicotine implications for long term use ECs, reduced nicotine content cigarettes and the cigarette end game

Nicotine Mimics the Neurotransmitter Acetylcholine: Both Bind to Nicotinic Cholinergic Receptors

Major Safety Concerns for Nicotine Addiction Cardiovascular Disease Reproductive Toxicity Infectious disease risk Cancer Definite Probable Probable Possible Unlikely

E-cigarettes and Nicotine Addiction: Implications for EC use by Youth

Nicotine pharmacokinetic profile differs by delivery system could have implications for addiction and other toxicity

Plasma nicotine (ng/ml) 20 15 Nicotine PK with E-cigarette use during standardized session Subj 2, cartridge Subj 6, tank Subj 7, tank 10 5 0-15 0 15 30 45 60 75 90 105 120 135 150 165 180 Time after last of 15 puffs (min) (St. Helen, Addiction 2015)

Plasma nicotine (ng/ml) Plasma nicotine (ng/ml) Nicotine PK with ad libitum E-cigarette use 30 25 20 15 puff 10 Subj 4, RBA 5 0-15 0 15 30 45 60 75 90 30 25 20 puff 15 Subj 9, cartridge 10 5 0-15 0 15 30 45 60 75 90 Time after first puff (min)

Nicotine and Adolescent Brain Development Nicotine interferes with prefrontal cortex maturation

Adolescent Behavior and the Brain Increased risk-taking, impulsivity, noveltyseeking Increased vulnerability to initiation and subsequent addiction to drugs Incomplete development of the prefrontal cortex: decision making, impulse control and executive function

Nicotine effects on prefontal cortex (PFC) functions Nicotine in adolescent rats results in long-term cognitive impairment (accuracy, impulse control) Adolescent smokers show reduced PFC activity, including memory and attention Adolescent smoking associated with later life behavior disturbances, including substance abuse and mental health problems Early initiation of smoking associated with higher level of addiction in adulthood

Addiction risk is likely less for EC compared to conventional cigarettes PK profile different lower peak nicotine levels with usual patterns of use Cigarette smoke is more than nicotine MAOI inhibition augments nicotine brain effects Youth epidemiology finds much experimentation, occasional use, use of non-nicotine containing liquids. Most likely most youth progression from EC to regular use or cigarette smoking is NOT mediated by nicotine addiction.

Percent (%) Number of Days of 12 th Grade E-cigarette Use by Smoking Status, Last 30 Days 93.5 (Monitoring the Future, 2014) 42.7 3.9 16.7 1.0 13.0 0.5 6.9 0.5 6.1 0.7 14.7 Days of E-Cigarette Use (Warner, Am J Prev Med 2016)

Daily nicotine exposure with various patterns of EC use In former smokers, sole EC user have similar cotinine levels to typical cigarette smokers Experimental switching studies EC users can achieve similar nicotine intake to when smoking In the general population most dual users are non-daily EC users nicotine intake similar to smokers Dual users who use EC daily (and generally more advanced devices) report fewer CPD I could not locate studies on nicotine intake

Cardiovascular Toxicity of Cigarette Smoking and E- cigarettes: What Role Nicotine?

Constituents of tobacco smoke and EC aerosol that could contribute to CVD Oxidizing chemicals # Carbon monoxide * Volatile organic compounds # Particulates Heavy metals # Nicotine * Not present in EC aerosol # Present at much lower levels

CV Actions of Nicotine and Probable Contribution to Smoking-induced CVD Action Hemodynamic Endothelial Dysfunction Thrombogenesis Inflammation Arrhythmogenesis Lipid Abnormalities Insulin Resistance/Diabetes Myocardial Effects Probable Contribution Probable Possible Unlikely Unlikely Probable Possible Possible Possible

Mechanisms by which E-cigarettes could cause Acute CV Events E-cigarette Aerosol Oxidizing Chemicals Particulates Acrolein Inflammation Nicotine Sympathetic Nervous System Activation Catecholamine Release Ventricular Arrhythmogenesis Platelet Activation Thrombosis Endothelial Dysfunction Coronary Vasoconstriction Heart Rate Blood Pressure Myocardial Contractility Myocardial Blood Flow Coronary Occlusion Myocardial Ischemia Myocardial Infarction Myocardial Demand for oxygen and nutrients Sudden Death

Epinephrine µg /g creatinine Epinephrine Excretion: Cigarette Smoking, E-Cigarettes, Abstinence n=14 * p < 0.05 Study Arm

Health Effects of Smokeless Tobacco: Natural Experiment on Effects of Nicotine without Combustion Toxicants

American snus Swedish snus www.trinketsandtrash.org

Smokeless tobacco and CVD: Swedish snus Similar daily nicotine exposure, but slower absorption No effect on platelet activation or carotid intimal thickness Case control studies no increase in risk of MI or stroke; small but significant increase in case fatality Increased mortality with continued snus after MI Increased risk of heart failure, but not atrial fibrillation

Continued Snus Use After Myocardial Infarction Increases Mortality Mortality (per 1000 pyr) 30 28.4 SWEDEHEART MI register 2474 snus users - 27% Quit 20 18.7 6934 smokers 61 % Quit 2 year follow up % 10 9.7 13.7 0 Q U Q U Snus Cigarettes (Arefalk, 2014)

Conclusions: Nicotine and Cardiovascular Disease Biological plausibility and epidemiological evidence that nicotine may contribute to acute CV events Short term nicotine use poses little CV risk Long term nicotine use may be harmful in the presence of CVD Nicotine is much less hazardous than smoking and replacing cigarettes with ANDS would be a substantial benefit for public health

Swedish Snus and Other Health Effects Increase in pancreatic and esophageal, but not other cancers likely nitrosamine effect Reproductive toxicity: higher risk of preeclampsia, reduced birth weight No increase in lung disease

Reduced Nicotine Content Cigarettes, E-cigarettes and the Cigarette End Game

Two approaches to reducing or eliminating the use of combusted tobacco products Reducing nicotine content of cigarettes to non-addicting levels Promoting the use of non-combusted forms of nicotine (such as NRT, ANDS)

NICOTINE AVAILIBILITY Reducing Addictiveness of Cigarettes: A Nicotine Reduction Strategy Addiction Threshold 0 5 10 15 20 YEARS

Clinical trials of reduced nicotine content cigarettes Smokers do not like RNC Smokers do reduce daily nicotine intake (by 65%), but 80% are not fully compliant with RNC Smokers of RNC seek alternative sources of nicotine in particular high reward value situations (such as first cigarette of day)

Concerns with free marketing of e-cigarettes for harm reduction Unlikely to out-compete conventional cigarettes Most EC users are dual users, with possible adverse effects on quitting smoking Attraction of youth and gateway to cigarettes Re-normalization of smoking-like behaviors

The complementary roles of nicotine reduction and non-combusted nicotine products ANDS provide ready availability of consumeracceptable non-combusted nicotine to support shift away from nicotine from cigarettes Cigarette nicotine reduction not perceived as nicotine prohibition Dual use less likely because RNC are less satisfying and less desirable Gateway from EC to cigarettes for adolescents obviated because RNC minimally addictive

Regulatory context When faced with RNC many smokers may be motivated to quit smoking; and for those who continue to seek nicotine, ECs are likely the most acceptable alternative source The RNC cigarette and the emergence of attractive non-combusted nicotine products should be viewed as complementary components of a national intervention that could virtually end combusted tobacco use Regulations regarding ECs should focus on toxicity, safety and limiting youth access but should not disrupt features that make them a viable alternative to cigarettes, including (safe) flavors